pays attention to SynTao Ventures, not lost on the road to venture capital
SynTao Ventures learned on November 8 that , an innovative biopharmaceutical company, Apollomics recently announced the completion of a US$124 million Series C financing, funded by Ping An Capital Leading the investment, several investors followed up. This round of financing is mainly used to support the development of Guanke Meibo's product pipeline with APL-101 and APL-106 as the core. In addition, Dr. Dong Liu of Ping An Capital will join the board of directors of Guanke Meibo.
takes the eradication of cancer as the company's mission.
Apollomics was founded in 2016 and is committed to the development of tumor targeting and immune single drugs and their combination therapies to improve the lives of cancer patients. The company's name "Apollomics" is derived from the Greek verb "apollymi", which means "destruction", meaning to eliminate cancer. In addition, Guanke Meibo has operating entities in Hangzhou, China and Foster City, California, USA.
APL-101 is a new type of oral and highly selective c-MET inhibitor developed by Guanke Meibo, which has shown tumor suppressive effect in gastric cancer, liver cancer, pancreatic cancer and lung cancer; and APL-106 (Uproleselan) is the world's first innovation (first-in-class), is a targeted E-selectin antagonist. It has been approved by the US Food and Drug Administration (FDA) for breakthrough therapy in clinical research for the treatment of relapsed or refractory adult acute myeloid leukemia .
Guankemeibo said that the C round of financing will continue to support the company to implement three new strategies to fight tumors. Mainly include: 1. Use combination therapy to increase the response rate of PD1 antibody; 2. Inhibit tumor resistance mechanism, including activating the escape mechanism of c-Met signal to achieve better targeted therapy effect; 3. Prevent tumor cells Hide in the bone marrow and other organs to prevent the anti-cancer drugs from finding the tumor cells, thereby enhancing the effect of the anti-cancer drugs. What is the next step of the
financier Guanke Meibo?
Yu Guoliang, the founder and chairman of Guankemeibo, said that Guankemeibo has been focusing on precision medicine. With the help of this round of financing, Guankemeibo will continue to promote the development of the current product pipeline and expand the company's The project will bring more innovative therapies for specific mutations, amplification and resistance mechanisms to patients, and continue the grand blueprint of Guankemeibo. What is the reason for the investment of
investor Ping An Capital? Ping An Capital, the investor of
, stated that since its establishment, Guanke Meibo has established a rich pipeline of single-drug and combination therapy products through independent research and development and strategic cooperation, and has made good progress. At present, the company's product pipeline has many projects at different stages of research and development, and multiple clinical trials are being carried out. It is believed that Guankemeibo will continue to maintain the momentum of progress, and Ping An Capital will continue to be optimistic about the development of Guankemeibo.
How does SynTao Venture Capital.com comment on this financing event? Viewpoint of Wang Shuai, founder of
SynTao Ventures: Since its establishment in 2016, Guanke Meibo has received more than US$200 million in financing. The research and development of the project has been accelerating continuously, covering many aspects such as non-small cell lung cancer and malignant glioma. I believe that after this round of financing, through the injection of funds, Guankemeibo will continue to develop, and I hope it will bring the gospel to more patients.
original author: Wu Moon Hee
official review: Zofia
Published: 2020 November 8
the original copyright: Road to venture net Shu having a national identity of the venture capital circles ecological services provider, is committed to the prosperity and development of Chinese venture capital circles And work hard!
